ATE460174T1 - Gezielte proteine abbauträger, dafür kodierende nukleinsaüre und deren verwendung - Google Patents

Gezielte proteine abbauträger, dafür kodierende nukleinsaüre und deren verwendung

Info

Publication number
ATE460174T1
ATE460174T1 AT03767704T AT03767704T ATE460174T1 AT E460174 T1 ATE460174 T1 AT E460174T1 AT 03767704 T AT03767704 T AT 03767704T AT 03767704 T AT03767704 T AT 03767704T AT E460174 T1 ATE460174 T1 AT E460174T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid coding
targeted proteins
proteins degradation
carrier
Prior art date
Application number
AT03767704T
Other languages
English (en)
Inventor
Claudia Buerger
Bernd Groner
Kerstin Nagel-Wolfrum
Christian Kunz
Ilka Wittig
Original Assignee
Speyer Georg Haus Chemo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speyer Georg Haus Chemo filed Critical Speyer Georg Haus Chemo
Application granted granted Critical
Publication of ATE460174T1 publication Critical patent/ATE460174T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/72Fusion polypeptide containing domain for protein-protein interaction containing SH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
AT03767704T 2002-11-29 2003-11-28 Gezielte proteine abbauträger, dafür kodierende nukleinsaüre und deren verwendung ATE460174T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026850A EP1426055A1 (de) 2002-11-29 2002-11-29 Gezielte Proteine Abbauträger, kodierende Nukleinsäure dafür und deren Verwendung
PCT/EP2003/013436 WO2004050113A1 (en) 2002-11-29 2003-11-28 TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE

Publications (1)

Publication Number Publication Date
ATE460174T1 true ATE460174T1 (de) 2010-03-15

Family

ID=32309356

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767704T ATE460174T1 (de) 2002-11-29 2003-11-28 Gezielte proteine abbauträger, dafür kodierende nukleinsaüre und deren verwendung

Country Status (5)

Country Link
EP (2) EP1426055A1 (de)
AT (1) ATE460174T1 (de)
AU (1) AU2003292158A1 (de)
DE (1) DE60331688D1 (de)
WO (1) WO2004050113A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392585A3 (de) * 2007-10-17 2012-02-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gerüstproteine für rekombinante Peptidaptamere
US12016902B2 (en) 2017-04-04 2024-06-25 Loma Linda University Biologic for the treatment of cancer
CN112662676B (zh) * 2020-12-30 2023-12-29 南方科技大学 一种dna编码靶向水解蛋白的多肽或者蛋白的方法
CN119495366B (zh) * 2023-08-15 2025-12-05 华东师范大学 一种可编程调控的蛋白质靶向降解系统、构建及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
AU781992B2 (en) * 2000-04-04 2005-06-23 Medical Research Council Methods involving induced dimerisation by cellular components
CA2407945A1 (en) * 2000-05-04 2001-11-08 Mount Sinai Hospital Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same
EP1205191A1 (de) * 2000-11-13 2002-05-15 Centre National De La Recherche Scientifique Zielgerichte Änderung von intrazellular Verbindungen

Also Published As

Publication number Publication date
AU2003292158A1 (en) 2004-06-23
WO2004050113A1 (en) 2004-06-17
EP1426055A1 (de) 2004-06-09
DE60331688D1 (de) 2010-04-22
EP1605964B1 (de) 2010-03-10
EP1605964A1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
CY1120257T1 (el) ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS
EP1649006A4 (de) Exo-spezifische amylase-polypeptide, diese polypeptide codierende nukleinsäuren und verwendungen davon
PL3085783T3 (pl) Przeciwciało biswoiste zastępujące białka funkcjonalne
ATE384736T1 (de) Subzelluläres targeting von therapeutischen proteinen
ATE503009T1 (de) Polypeptide mit lipase-aktivität und diese kodierende polynukleotide
IL187389A0 (en) Nucleic acid molecule encoding a conjugate for treating activated immune cells
SI2322552T1 (sl) IL-1beta vezavna protitelesa in njihovi fragmenti
ATE249209T1 (de) Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
SG2013005590A (en) Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
BR0300255B1 (pt) veÍculo dotado de lanterna traseira.
DE60239729D1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
WO2005047459A3 (en) Sars nucleic acids, proteins, antibodies, and uses thereof
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
AT500634B8 (de) Fahrzeugscheinwerfer mit heizung
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
ATE340259T1 (de) Kationisches vehikel: dns komplexe und ihre verwendung in gentherapie
ATE460174T1 (de) Gezielte proteine abbauträger, dafür kodierende nukleinsaüre und deren verwendung
DE69823732D1 (de) Kautschukzusammensetzung mit verbesserten antistatischen Eigenschaften, sowie daraus hergestellter Reifen
WO2001066752A3 (en) Reproduction-specific genes
BRPI0403778A (pt) Veìculos condutores revestidos
WO2004046166A3 (en) Modified alpha-msh peptides and derivatives thereof
BR0005096B1 (pt) conjunto de suspensço de veÍculo.
ATE528392T1 (de) Neues protein und dessen dns

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties